Related Experiment Video
Updated: Jun 22, 2026
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
When is prophylaxis for hereditary angioedema necessary?
Timothy Craig1, Marc Riedl, Mark S Dykewicz
1Department of Medicine and Pediatrics, Pennsylvania State University, College of Medicine, Hershey, Pennsylvania 17033, USA. tcraig@psu.edu
Insights
Newer agents like C1 esterase inhibitor protein (C1-INH) offer an alternative prophylaxis for hereditary angioedema (HAE) attacks. Consider C1-INH for patients experiencing frequent, severe attacks or those intolerant to androgen therapy.
Area of Science:
- Immunology
- Genetics
- Pharmacology
Background:
- Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling attacks.
- Androgens are a traditional prophylaxis for HAE but have significant adverse events.
- Newer agents, including C1 esterase inhibitor protein (C1-INH), are emerging as alternatives.
Purpose of the Study:
- To determine the appropriate timing and indications for considering C1-INH prophylaxis for HAE.
- To evaluate C1-INH as an alternative to androgen therapy, considering its efficacy and safety profile.
Main Methods:
- A comprehensive literature review of HAE therapy was conducted.
- Guideline reviews and expert panel discussions informed the decision-making process.
- Articles on HAE treatment published in peer-reviewed literature were selected for analysis.
Main Results:
- C1-INH has demonstrated efficacy for HAE prophylaxis, with a favorable half-life for this use.
- The short half-lives of other agents (ecallantide, icatibant, recombinant human C1-INH) limit their prophylactic utility.
- Specific patient criteria, including attack frequency, severity, quality of life, and previous severe events, indicate the need for prophylaxis.
Conclusions:
- C1-INH prophylaxis should be considered for HAE patients with frequent or severe attacks, laryngeal involvement, or significant quality of life impairment.
- Patients experiencing androgen intolerance, adverse reactions, or failure of androgen therapy are prime candidates for C1-INH prophylaxis.
- Prophylaxis decisions should be individualized based on patient-specific factors and treatment history.
Objective:
To determine when newer agents, such as C1 esterase inhibitor protein (C1-INH), should be considered as prophylaxis to decrease hereditary angioedema (HAE) attacks as an alternative to androgens, which have significant adverse events.
Data Sources:
A literature review (PubMed, Google, and Ovid), guideline review, expert panel meeting, and group discussion were performed to decide when prophylaxis is indicated.
Study Selection:
Articles addressing HAE therapy published in the peer-reviewed literature were selected.
Results:
The retrieved studies demonstrate that C1-INH is effective and that the half-life makes it attractive for prophylactic use. The short half-lives of ecallantide, icatibant, and recombinant human C1-INH limit their use as prophylactic agents. Patients with severe anxiety, more than 1 attack per month, rapid progression of attacks, limited access to health care, more than 10 days lost from work or school per year, previous laryngeal swelling, more than 3 emergency department visits per year, more than 1 hospitalization per year, previous intubation, previous intensive care unit care, significant compromise in quality of life, or narcotic dependency should be considered for androgen or C1-INH prophylaxis therapy.
Conclusion:
Patients with HAE with frequent attacks, severe attacks, past laryngeal attacks, excessive loss of work or school, significant anxiety, and poor quality of life should be considered for C1-INH prophylaxis, especially those who fail, are intolerant of, have adverse reactions to, or are not candidates for androgen therapy.
Related Concept Videos
02:06Allergic Reactions
01:30Allergic Reactions: Anaphylaxis
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Angina IV: Management
01:21Rheumatic Heart Disease III: Medical Management
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy